Originally posted 3/6/2013
A late post tonight, since my new exercise program has pushed my blogging back by an hour or so each night. My suspicions about exercise were correct, by the way; it is much easier to suggest exercise to other people than it is to actually exercise. I’ve been at it since the beginning of the year, and I at least feel a bit less hypocritical.
While I’m on the topic… I’ve received many comments over the years from people complaining that they’ve been taking Suboxone or buprenorphine for X many years, and they have no energy, they feel stressed, they have gained weight, they don’t sleep well or they sleep TOO well… and concluding that all of the problems are from Suboxone.
Suboxone causes… everything!
They aren’t (from Suboxone). Not at all. But I wonder, at this point, if regular readers of my blog know EXACTLY what I’m going to say. I’m tempted to stop typing and ask people answer so I get a sense of how predictable I’ve become. But then I’d have to wait and then come back, read, and assess the situation…. I really can’t imagine much positive to come out of THAT experience, so I’ll just finish my thoughts, about the problems that people often blame on Suboxone.
This is a preview of
Suboxone Makes Me Fat and Boring and Stupid
. Read the full post (718 words, estimated 2:52 mins reading time)
Originally Posted 3/3/2013
What a crazy week for buprenorphine. I’ve written about the FDA slapping the face of Reckitt Benckiser by denying their Citizens’ Petition. Adding insult to injury, the FDA then approved two generic formulations of Suboxone tabs (actually, the correct name is buprenorphine/naloxone combination tabs). Stock in RB dropped about 5%, but shares regained most of their price within a couple days, reflecting the balance of pessimism vs. optimism in the company’s ability to maintain stellar profit growth going forward.
In case anyone is wondering, I do not own shares in Reckitt Benckiser, and I have never owned shares in Reckitt Benckiser. One nice thing about NOT having significant savings, I supposed, is that I can report my holdings (or lack of holdings) without too much effort!
If I WAS an investor, though, I’d wonder about the future of Reckitt Benckiser’s Suboxone, now that two generic competitors are hitting the market. Some patients clearly prefer the tablet over the film; will state medicaid agencies go back to covering the tablet, which will likely be cheaper than the film? Will insurers cover the tabs? Or will both groups continue to buy into the marketing scheme of Reckitt-Benckiser, and the company’s claim that only the film is ‘safe’?
For those who missed my explanation, I’m adding these old posts to reconstruct the archive. The site’s database was damaged by something, somehow… New posts coming soon.
Find a copy of the response here, or at this url:www.suboxonetalkzone.com/cpresponse.pdf